Maxigen Biotech Inc (1783) — Working Capital to Net Assets Ratio
Maxigen Biotech Inc (1783) has a Working Capital to Net Assets ratio of 50.7% as of March 2026. Working capital of NT$824.59 Million (current assets of NT$1.18 Billion minus current liabilities of NT$355.51 Million) is measured against net assets of NT$1.63 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 1783 net asset quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Maxigen Biotech Inc Working Capital to Net Assets (2009–2025)
This chart shows how Maxigen Biotech Inc's Working Capital to Net Assets ratio has evolved across 17 annual periods from 2009 to 2025. As of March 2026, the ratio stands at 50.7%, reflecting working capital of NT$824.59 Million against net assets of NT$1.63 Billion TWD. Check 1783 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Maxigen Biotech Inc (2009–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Maxigen Biotech Inc from 2009 to 2025, covering 17 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 1783 stock market capitalisation.
| Year | WC/NA Ratio | Working Capital (TWD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 50.2% | NT$772.36 Million | NT$1.54 Billion | NT$1.12 Billion | NT$349.11 Million | ▲ +4.8 pp |
| 2024 | 45.4% | NT$624.47 Million | NT$1.38 Billion | NT$830.33 Million | NT$205.87 Million | ▲ +9.5 pp |
| 2023 | 35.9% | NT$488.19 Million | NT$1.36 Billion | NT$619.56 Million | NT$131.37 Million | ▼ -29.1 pp |
| 2022 | 65.0% | NT$841.75 Million | NT$1.30 Billion | NT$993.25 Million | NT$151.50 Million | ▲ +6.5 pp |
| 2021 | 58.5% | NT$667.49 Million | NT$1.14 Billion | NT$783.55 Million | NT$116.07 Million | ▲ +18.3 pp |
| 2020 | 40.2% | NT$345.47 Million | NT$860.23 Million | NT$432.06 Million | NT$86.58 Million | ▲ +2.8 pp |
| 2019 | 37.4% | NT$318.20 Million | NT$851.32 Million | NT$640.15 Million | NT$321.95 Million | ▲ +0.9 pp |
| 2018 | 36.4% | NT$307.14 Million | NT$842.98 Million | NT$599.52 Million | NT$292.39 Million | ▼ -26.6 pp |
| 2017 | 63.1% | NT$502.12 Million | NT$796.25 Million | NT$585.10 Million | NT$82.98 Million | ▲ +0.8 pp |
| 2016 | 62.2% | NT$486.34 Million | NT$781.38 Million | NT$574.01 Million | NT$87.68 Million | ▼ -14.8 pp |
| 2015 | 77.0% | NT$639.20 Million | NT$829.86 Million | NT$702.54 Million | NT$63.34 Million | ▲ +9.4 pp |
| 2014 | 67.6% | NT$593.03 Million | NT$877.01 Million | NT$658.09 Million | NT$65.06 Million | ▼ -15.6 pp |
| 2013 | 83.2% | NT$739.30 Million | NT$888.39 Million | NT$788.21 Million | NT$48.91 Million | ▲ +7.2 pp |
| 2012 | 76.0% | NT$292.99 Million | NT$385.66 Million | NT$333.02 Million | NT$40.04 Million | ▲ +1.9 pp |
| 2011 | 74.1% | NT$273.45 Million | NT$369.25 Million | NT$310.79 Million | NT$37.34 Million | ▼ -13.2 pp |
| 2010 | 87.2% | NT$344.81 Million | NT$395.39 Million | NT$379.11 Million | NT$34.30 Million | ▲ +5.2 pp |
| 2009 | 82.0% | NT$256.81 Million | NT$313.03 Million | NT$287.26 Million | NT$30.45 Million | — |